Development of a new treatment for high-grade neuroendocrine carcinoma of the lung targeting Stathmin1
Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
Date (from‐to) : 2019/04 -2022/03
Author : Shimizu Kimihiro
This study aims to clarify the effects of STMN1 PIP, an STMN1-specific inhibitor, on the proliferation, invasion, and anticancer drug sensitivity in refractory HGNET cells overexpressing microtubule destabilizing factor SMNN1. Therefore, we investigated the combined effect of STMN1-specific PIP with a taxane anticancer drug in a tumor-bearing mouse model. As a result, we observed a significant tumor reduction in the combination group compared to the control group, STMN1 alone, and the taxane alone group. Furthermore, in animal studies, STMN1 PIP administration did not cause significant side effects such as weight loss, suggesting that STMN1 PIP is a promising treatment tool for refractory HGNET.